Goldman Sachs raised the firm’s price target on Bristol Myers (BMY) to $57 from $51 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers upgraded to Buy at BofA on pipeline strength
- Bristol Myers upgraded to Buy from Neutral at BofA
- PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
- Midday Fly By: Broadcom slides, pot stocks jump
- Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls